About Cerecor
Cerecor is a publicly listed company based in Baltimore (United States) founded in 2011. Therapeutics for immunological and neurological disorders are developed. Cerecor has raised $45.2 million across 6 funding rounds from investors including NIH, Hercules Capital and Maxim Group. The company has 20 employees. Cerecor has completed 3 acquisitions, including Aevi Genomic Medicine, Karbinal ER and Trxpharma. Cerecor offers products and services including AVTX-009, Quisovalimab, and AVTX-008. Its focus areas include Life Sciences, Neurology, Drugs and Psychiatric. Its legal entity is AVALO THERAPEUTICS, INC. Its competitors include Nimbus Therapeutics, Escient Pharmaceuticals and Aclaris Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2011, Cerecor operates from Baltimore, United States, within the biotechnology sector. Focus is placed on developing treatments for immunological and neurological conditions. The pipeline encompasses CERC-002, targeted at pediatric Crohns disease; CERC-007, aimed at inflammatory arthritis and multiple myeloma; and CERC-802 along with CERC-803, directed toward congenital disorders. Efforts center on advancing these therapeutic candidates through clinical stages.
- Headquarters Baltimore, United States
- Employees 20
- Stage Public
- SectorsHealthcare
- Website cerecor.com
- Social LinkedIn
- Legal Name Avalo Therapeutics, Inc.
- Annual Revenue$18.05 M (USD)234as on Dec 31, 2022
- Total Equity Funding$45.2M (USD)
in 6 rounds
- Latest Funding Round$5M (USD), Post-IPO
Apr 2017
- InvestorsNIH
& 6 more
- Employee Count20
- Investments & AcquisitionsAevi Genomic Medicine
& 2 more
Products & Services of Cerecor
Cerecor offers a comprehensive portfolio of products and services, including AVTX-009, Quisovalimab, and AVTX-008.
Targets inflammatory diseases via anti-IL-1β for immune dysregulation
Anti-LIGHT mAb for treating immune dysregulation disorders
BTLA agonist to modulate immune responses in therapies
Funding Insights of Cerecor
Cerecor has successfully raised a total of $45.2M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $5 million completed in April 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $45.2M
- Total Rounds 6
- Last Round Post-IPO — $5M
- First Round $22.14M
(Apr 2012)
- Investors Count 7
All 6 funding rounds of Cerecor with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2017 | $5M | Post-IPO | – | – | |
| Sep 2016 | $1M | Post-IPO | – | – | |
| Apr 2016 | $1M | Grant | – | – | |
| Jul 2014 | $16.26M | Series B | – | MPM Capital, New Enterprise Associates | – |
| Sep 2013 | $6.81M | Series A | – | – | – |
| Apr 2012 | $22.14M | Series A | – | Maxim Group | – |
7 investors in total: 7 institutional.
Investors in Cerecor
Cerecor has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Hercules Capital and Maxim Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Apple Tree Partners is engaged in life sciences venture capital. | appletreepartners.com | |||
Global hedge fund managing long/short investments in health care and consumer sectors. | 2012 | armisticecapital.com | New York, United States | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com | |||
Financial advisory services are provided across multiple sectors. | 2002 | maximgrp.com | New York, United States |
Investor details for Cerecor
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cerecor
23 people are tracked at Cerecor (13 in leadership, 5 in board & advisors, 5 in team); the tracked headcount is 20.
| Name | Role | Group |
|---|---|---|
Yingping Zhang | VP, Head of IT/IS | Leadership |
Karen Dieterle | Sr. Director, Project Management | Leadership |
Jen Zoltoski, CPA | Vp, Corporate Controller | Leadership |
Paul Guptill | Vice President CMC Biologics | Leadership |
Mittie Doyle | Chief Medical Officer | Leadership |
Alan Mendelsohn | Vice President | Leadership |
Garry A. Neil | Chairman of the Board and Chief Executive Officer | Leadership |
Chris Sullivan | CFO | Leadership |
Michael McInaw | Finance Business Partner & Controller For R&d | Leadership |
Min Zhang | Director, CMC | Leadership |
Maura McGovern | Director SEC Reporting & Technical Accounting | Leadership |
Kathleen Frenia Cohen | Senior Vice President, Clinical Development Operations | Leadership |
Mary Scavello | Director, Hr, Benefits & Administration | Leadership |
Magnus Persson | Director | Board & advisors |
Mitchell Chan | Director | Board & advisors |
Sol J. Barer | Director | Board & advisors |
June Almenoff | Director | Board & advisors |
Gilla Kaplan | Director | Board & advisors |
Hector Hilton Jr. | Staff Accountant | Team |
Lisa Hegg | SVP, Program Management & Corporate Infrastructure & Clinical Operations | Team |
3 more people are available in the full profile.
Complete people profiles for Cerecor
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cerecor
Cerecor has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Aevi Genomic Medicine, Karbinal ER and Trxpharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutics for rare diseases in neurology and hematology are developed. | aevigenomics.com | Wayne, United States | 2001 | Dec 2019 | •••• | |
Information on allergy drugs is provided through an online platform. | karbinaler.com | Chesterfield, United States | 2011 | Feb 2018 | •••• | |
| trxpharma.com | United States | 0 | Nov 2017 | $23M |
Complete acquisition details for Cerecor
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Cerecor
7 dated milestones of Cerecor across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Cerecor is founded.
- Funding First funding round of $22.1M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $5.0M.
- Acquisition Acquires Trxpharma.
- Acquisition Acquires Karbinal ER.
- Acquisition Acquires Aevi Genomic Medicine.
Competitors of Cerecor
Cerecor has 3 listed competitors in our database, 3 of them funded. They include Nimbus Therapeutics, Escient Pharmaceuticals and Aclaris Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| escientpharma.com | 2017 | San Diego, United States | $237.5M | 44 | Small molecule therapeutics for inflammatory diseases are developed. | |
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. |
Detailed competitors of Cerecor
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cerecor
Websites that share an audience with Cerecor (cerecor.com).
Websites whose visitors overlap most with Cerecor. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| dicerna.com | 100% | View details | |||
| histogenics.com | 93% | View details | |||
| fiercebiotech.com | 89% | 858.3K | #81,022 | View details | |
advisorysurveys.com | advisorysurveys.com | 58% | – |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Cerecor (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cerecor
Complete news archive for Cerecor
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cerecor
Cerecor was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Cerecor is headquartered in Baltimore, United States. It is registered at Baltimore, Maryland, United States.
Cerecor is a funded company, having raised a total of $45.2M across 6 funding rounds to date. The company's 1st funding round was a Series A of $22.14M, raised on Apr 2012.
Cerecor has 20 employees.
Annual revenue of Cerecor is $18.05M as on Dec 31, 2022.
Founded in 2011, Cerecor operates from Baltimore, United States, within the biotechnology sector. Focus is placed on developing treatments for immunological and neurological conditions. The pipeline encompasses CERC-002, targeted at pediatric Crohns disease; CERC-007, aimed at inflammatory arthritis and multiple myeloma; and CERC-802 along with CERC-803, directed toward congenital disorders. Efforts center on advancing these therapeutic candidates through clinical stages.
Cerecor's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Aclaris Therapeutics.
Cerecor offers AVTX-009, Quisovalimab, and AVTX-008.
Cerecor has made 3 acquisitions, including Aevi Genomic Medicine, Karbinal ER, and Trxpharma.
Cerecor has 7 investors. Key investors include NIH, Hercules Capital, Maxim Group, Armistice Capital, and Turmeric Acquisition Corp.
Cerecor operates through Avalo Therapeutics, Inc..